Test Directory

Immunoglobulin Gene Clonality

Containers - Adult

RedCapTubeEDTAKE2.7ml.jpg
Red Cap Tube EDTA KE 2.7ml
Volume Range

​5ml peripheral blood, bone marrow specimen or FFPE tissue

Additive per Container

​EDTA
path_block_slide.jpg
FFPE block / H&E slide / Pathology report

Laboratory Site

WGH
Crewe Road South
Edinburgh
EH4 2XU
Telephone: 0131 537 1000

Transport arrangements

Specimens should ideally arrive within 24 hours of collection (maximum of 48 hours).  There is no time limit for FFPE samples.  Samples should be sent to the following address:

Western General Hospital

Haematology/Biochemistry Combined Reception

Immunophenotyping Laboratory

Crewe Road

Edinburgh

EH4 2XU​

 

See also Specimen transportation.

Sample storage arrangements

Samples should be stored at room temperature. See specimen requirements.​

How to request

Please refer to our detailed requesting ​instructions.  The HMDS request form can be located here.​

 

Requests for testing FFPE tissue should be sent to the Molecular Pathology Service at RIE with a completed HMDS test request form.

Availability

Monday - Friday 9am-5pm

Anticipated turnaround

Results should be expected within 10 working days.  See results.

What happens if the result is positive or abnormal

Requesting clinician will be contacted via telephone or email. Please ensure details are included on request form.

Static information/disclaimer

IG gene rearrangement studies include assessment of IGH, IGK and IGL gene loci. See testing.

IG gene rearrangement assessment is undertaken using the BIOMED‐2 designed assays, with a standard PCR protocol and primer sets designed to target the IGH, IGK and IGL loci. Clonality assessment is a useful tool to aid with the diagnosis of B cell lymphoproliferative disorders. However, the results should always be interpreted in conjunction with morphology, immunophenotyping and/or immunohistochemistry results as well as the clinical findings.

This assay is not suitable for the assessment of low level minimal residual disease in acute leukaemia or lympoproliferative neoplasms.

For details on the interpretation of results, please see Langerak et al., Leukemia 2012; 26:2159-2171

This test is accredited to ISO 15189:2012

For clinical advice on appropriate investigations and advice for the interpretation of test results, please see contact us​.